英国药品患者说明书中药物基因组学指导内容的一致性与清晰度:横断面分析
该横断面分析审查了英国批准的所有具有强证据支持PGx处方推荐(CPIC A级或临时A/B级)的药品,发现80%的SmPC包含PGx信息但仅33%的PIL反映该信息,且PIL中PGx内容平均阅读年龄为19.1年,远高于英国典型阅读年龄9-11年。
要点
- 281/353(80%)SmPC含PGx信息,但仅115/353(33%)PIL反映此信息。
- PIL中PGx内容平均阅读年龄为19.1年,远高于英国典型9-11年。
- PIL中PGx信息不一致可能削弱患者理解与安全个体化处方。
核心结论
- PIL中PGx信息覆盖不一致且可读性差,可能影响患者理解和安全个体化用药。
研究设计与样本
- 横断面分析,审查353个英国批准且具强证据支持PGx处方推荐(CPIC A级或临时A/B级)的药品。
- 使用关键词搜索识别SmPC和PIL中PGx内容,并用Flesch-Kincaid分级评估PIL中PGx信息的阅读年龄。
主要发现
- 353个产品中,281个(80%)SmPC含PGx信息,但仅115个(33%)PIL反映该信息。
- PIL中PGx内容平均阅读年龄为19.1年,远高于英国典型阅读年龄9-11年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK-approved medicines with strong evidence supporting a PGx prescribing recommendation (CPIC Levels A or provisional A/B) were reviewed, using keyword searches to identify relevant content and estimating the reading age of PGx information in PILs using the Flesch-Kincaid grade level. Among 353 products, 281 (80%) SmPCs contained PGx information, but this was reflected in only 115 (33%) PILs. Where present, the PGx content in PILs required an average reading age of 19.1 years, far exceeding the typical UK reading age of 9-11 years. As the availability of genomic data becomes increasingly routine, the variable PGx information provided in PILs risks undermining patient understanding, engagement and safe personalized prescribing.
引用
- Narlawar P, Ratcliffe C, Sharma V, et al. Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross-sectional analysis. Br J Clin Pharmacol. 2026. PMID: 41834185. doi:10.1002/bcp.70521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。